Latest revenue
$156.4M
as of 2026-03-31
Latest net income
$-721.8M
as of 2026-03-31
Net margin
-461.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.11B
- Enterprise value
- $2.11B
- P/E (trailing)
- 8.0×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $11.31
- 52-wk low
- $6.00
- Beta
- —
- Shares out
- 254.2M
5-year trend
What this company does
ITEM 1. BUSINESS Our Business We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. Our business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in class oral small molecule and injectable protein therapeutics…
AI summary unavailable — showing raw filing excerpt
Generated from BCRX's filing dated 2026-02-26
Key risks
Table of Contents ITEM 1A. RISK FACTORS An investment in our stock involves risks. You should carefully read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial condition or results of operations, along with all of the other information included in our other filings with the SEC, before making an investment decision regarding our common stock. Additionally, while some of the factors, events and contingencies described herein may have occurred in the past, the disclosures herein are not representations as to whether or not they have occurred and are instead provided because future occurrences thereof could adversely affect…
AI summary unavailable — showing raw filing excerpt
Generated from BCRX's filing dated 2026-02-26
Profitability
Operating margin
39.0%
7008.2%Net margin
30.2%
252.9%Return on equity
-221.4%
1285.8%Return on assets
51.3%
383.2%Leverage
Debt / equity
-5.32×
161.8%Long-term debt / equity
-0.01×
98.2%Debt / assets
123.2%
37.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $156.4M | +7.5% | $-721.8M | -2255762.5% | -461.5% |
Q4 2025 2025-12-31 | $406.6M | +209.1% | $245.8M | +1017.5% | 60.5% |
Q3 2025 2025-09-30 | $159.4M | +36.1% | $12.9M | +191.9% | 8.1% |
Q2 2025 2025-06-30 | $163.4M | +49.4% | $5.1M | +140.1% | 3.1% |
Q1 2025 2025-03-31 | $145.5M | +56.9% | $32.0K | +100.1% | 0.0% |
Q4 2024 2024-12-31 | $131.5M | — | $-26.8M | — | -20.4% |
Q3 2024 2024-09-30 | $117.1M | +35.0% | $-14.0M | +61.2% | -12.0% |
Q2 2024 2024-06-30 | $109.3M | +32.5% | $-12.7M | +83.2% | -11.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on BCRX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$4.7M
Net activity
−$4.7M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns BCRX
Institutional value
$911.5M
Total shares held
99.3M
Distinct holders
166
-105 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 22.7M | $215.6M | +1.5M (+7.2%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11.2M | $107.0M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 11.1M | $106.0M | — | New |
| 4 | abrdn plc | 5.0M | $48.0M | +4.1M (+451.7%) | Added |
| 5 | UBS Group AG | 4.9M | $47.1M | -319.9K (-6.1%) | Trimmed |
| 6 | Nuveen, LLC | 3.8M | $36.4M | +206.9K (+5.7%) | Added |
| 7 | RFG Advisory, LLC | 2.9M | $27.3M | — | New |
| 8 | Fisher Asset Management, LLC | 2.7M | $26.0M | +265.7K (+10.8%) | Added |
| 9 | OP Asset Management Ltd | 2.5M | $25.7M | +2.4M (+1700.0%) | Added |
| 10 | DIMENSIONAL FUND ADVISORS LP | 2.7M | $25.6M | +1.5M (+119.0%) | Added |
| 11 | Candriam S.C.A. | 2.3M | $21.8M | — | New |
| 12 | STIFEL FINANCIAL CORP | 1.8M | $17.4M | +667 (+0.0%) | Added |
| 13 | VANGUARD FIDUCIARY TRUST CO | 1.7M | $15.8M | — | New |
| 14 | JPMORGAN CHASE & CO | 1.5M | $14.6M | +698.6K (+82.8%) | Added |
| 15 | Legal & General Group Plc | 1.4M | $13.4M | +1.2M (+568.8%) | Added |
| 16 | Invesco Ltd. | 1.3M | $12.5M | -46.1K (-3.4%) | Trimmed |
| 17 | BNP PARIBAS FINANCIAL MARKETS | 1.3M | $12.4M | -1.2M (-48.8%) | Trimmed |
| 18 | JUPITER ASSET MANAGEMENT LTD | 1.2M | $11.4M | -1.2K (-0.1%) | Trimmed |
| 19 | DEUTSCHE BANK AG\ | 821.4K | $7.8M | +330.3K (+67.3%) | Added |
| 20 | FIRST TRUST ADVISORS LP | 800.9K | $7.6M | +425.9K (+113.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once BCRX's latest filing finishes processing.